Caladrius Biosciences Inc. (CLBS) Given Consensus Recommendation of “Buy” by Brokerages

Caladrius Biosciences Inc. (NASDAQ:CLBS) has received an average rating of “Buy” from the six research firms that are currently covering the firm. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $6.63.

Several brokerages have recently commented on CLBS. HC Wainwright restated a “buy” rating on shares of Caladrius Biosciences in a research report on Wednesday, August 10th. Zacks Investment Research upgraded shares of Caladrius Biosciences from a “hold” rating to a “strong-buy” rating and set a $6.75 target price for the company in a research report on Tuesday, August 2nd. Finally, Chardan Capital assumed coverage on shares of Caladrius Biosciences in a research report on Tuesday, August 23rd. They issued a “buy” rating and a $6.50 target price for the company.

An institutional investor recently bought a new position in Caladrius Biosciences stock. Hollencrest Securities LLC bought a new position in Caladrius Biosciences Inc. (NASDAQ:CLBS) during the third quarter, according to its most recent filing with the SEC. The institutional investor bought 122,911 shares of the company’s stock, valued at approximately $570,000.

Caladrius Biosciences (NASDAQ:CLBS) traded up 2.13% during midday trading on Wednesday, reaching $4.32. 7,785 shares of the company’s stock traded hands. The stock’s 50 day moving average price is $4.67 and its 200 day moving average price is $5.63. Caladrius Biosciences has a 1-year low of $4.00 and a 1-year high of $15.00.

Caladrius Biosciences (NASDAQ:CLBS) last issued its earnings results on Tuesday, August 9th. The company reported ($1.33) EPS for the quarter, beating the consensus estimate of ($1.75) by $0.42. The company earned $8.30 million during the quarter, compared to analysts’ expectations of $7.53 million. Caladrius Biosciences had a negative net margin of 220.23% and a negative return on equity of 163.53%. Equities research analysts expect that Caladrius Biosciences will post ($6.17) earnings per share for the current year.

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc, formerly NeoStem, Inc, through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development.

5 Day Chart for NASDAQ:CLBS

Receive News & Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.